Particle engineering company Nanoform has announced that AstraZeneca is performing an evaluation of Nanoform’s Controlled Expansion of Supercritical Solutions (CESS) technology “across a range of AstraZeneca’s proprietary pharmaceutical products.” According to the Nanoform, its technology can produce particles as small as 10nm.
Over the past few years, the company has announced the appointments of a number of people with significant experience in inhaled drug delivery, including former AstraZeneca researcher Niklas Sandler as Chief Technology Officer and three former Hovione employees: Chief of Business Operations Gonçalo Andrade, Director of Project Management Miguel Cansado, and Vice Chairman of the Board Miguel Calado.
Nanoform CEO Edward Hæggström commented, “Producing tailored nanoparticles <200nm from solution, in a controlled and reproducible manner, with good yield and without the need for excipients is highly challenging to do by current pharmaceutical manufacturing techniques or processes. This is the first step of hopefully a long and successful relationship between our two companies and we look forward to working closely with AZ to support their early development needs and validating the value of our technology for their products.”
Read the Nanoform press release.
